Literature DB >> 26706619

Evolution of Corneal Graft Survival Over a 30-Year Period and Comparison of Surgical Techniques: A Cohort Study.

Mélanie Bidaut-Garnier1, Elisabeth Monnet2, Aurélien Prongué3, Romain Montard3, Anne-Sophie Gauthier4, Maxime Desmarets5, Anne-Sophie Mariet6, Charlène Ratajczak7, Delphine Binda5, Maher Saleh4, Bernard Delbosc4.   

Abstract

PURPOSE: To compare graft survival between 3 10-year periods and according to surgical techniques performed in the last years.
DESIGN: Cohort study.
METHODS: setting: Regional center (Besançon University Hospital, France). PATIENTS: All 1132 patients operated on between 1983 and 2014. Graft and patient baseline characteristics, risk factors for failure, surgical procedures, and postoperative corneal status were collected. MAIN OUTCOME MEASURES: Five-year survival rate in the whole cohort; 1-year and 3-year survival rates, respectively, among 88 patients with endothelial dystrophy (ED) or postoperative bullous keratopathy (PBK) operated on using endothelial lamellar keratoplasty (ELK) or penetrating keratoplasty (PK), and among 56 patients with keratoconus operated on using anterior lamellar keratoplasty (ALK) or PK.
RESULTS: Between the 1983-1993 and the 2004-2014 periods, overall 5-year graft survival rate increased from 61.4% to 76.5% (P = .0004). The main prognostic factors were preoperative diagnosis, graft endothelial density, and postoperative lens status. After adjusting for these factors, difference in survival rates was no longer significant (hazard ratio 0.90 for the second and 1.17 for the third period, compared to the first, P = .4191). Only 1 graft failure, after PK, occurred among the 56 patients with keratoconus. Among the 88 patients with ED or PBK, the 1-year graft survival was higher with PK (90.6%) than with ELK (60.8%) (P = .0025) but no significance remained after adjustment (hazard ratio 3.22, P = .1304).
CONCLUSIONS: Despite numerous changes in graft procedures and surgical techniques, no noticeable improvement in graft survival was found during the last 30 years while taking into account other prognostic factors.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26706619     DOI: 10.1016/j.ajo.2015.12.014

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  Indications and graft survival analysis in optical penetrating keratoplasty in a tertiary care center in North India: a 5-year study.

Authors:  Sudesh Kumar Arya; Amit Raj; Ravi Kant Bamotra; Anubha Bhatti; Jyoti Deswal; Meenakshi Sindhu
Journal:  Int Ophthalmol       Date:  2017-07-07       Impact factor: 2.031

2.  Da Vinci Xi Robot-Assisted Penetrating Keratoplasty.

Authors:  Jimmy Chammas; Arnaud Sauer; Joëlle Pizzuto; Fabienne Pouthier; David Gaucher; Jacques Marescaux; Didier Mutter; Tristan Bourcier
Journal:  Transl Vis Sci Technol       Date:  2017-06-20       Impact factor: 3.283

3.  A comparative, retrospective, observational study of the clinical and microbiological profiles of post-penetrating keratoplasty keratitis.

Authors:  I-Huang Lin; Yi-Sheng Chang; Sung-Huei Tseng; Yi-Hsun Huang
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

4.  Risk factors for graft failure after penetrating keratoplasty.

Authors:  Rafael Ignacio Barraquer; Luis Pareja-Aricò; Alba Gómez-Benlloch; Ralph Michael
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

5.  Five Years Pathological Evaluation of Corneal Regrafts: A Study from Southern Iran.

Authors:  Masoomeh Eghtedari; Mahmood Kamalzadeh; Masoud Yasemi; Hossein Movahedan; Mohammad Javad Ashraf
Journal:  J Ophthalmol       Date:  2020-11-04       Impact factor: 1.909

6.  Lymphatic vessels identified in failed corneal transplants with neovascularisation.

Authors:  Michael Adam Diamond; Sze Wah Samuel Chan; Xun Zhou; Yelena Glinka; Eileen Girard; Yeni Yucel; Neeru Gupta
Journal:  Br J Ophthalmol       Date:  2018-10-22       Impact factor: 4.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.